Can I read Is there a difference in PFS or OS of T790M-mutated NSCLC patients treated with osimertinib either after chemotherapy or immediately after previous target therapy? on EtoBox?

Is there a difference in PFS or OS of T790M-mutated NSCLC patients treated with osimertinib either after chemotherapy or immediately after previous target therapy? by C.H. Lai; M.-C. Lin; Y.-H. Tsai; C.-C. Wang is a Medicine article available to read on EtoBox.

What is Is there a difference in PFS or OS of T790M-mutated NSCLC patients treated with osimertinib either after chemotherapy or immediately after previous target therapy? about?

Background: The irreversible ErbB family blocker, afatinib, is approved for first-line treatment of metastatic NSCLC harbouring non-resistant EGFR mutations. While afatinib has demonstrated a predictable and manageable safety profile in pts with EGFR mutation-positive (EGFRmþ) NSCLC, elderly pts are often under-represented in clinical trials. Here, we summarise the current status of, and preliminary data from, an ongoing Phase IV trial of afatinib in elderly pts with Del19/L858R EGFRmþ NSCLC (NCT02514174). Methods: Pts aged 70 yrs with Stage IV/recurrent Del19/L858R EGFRmþ NSCLC naı ̈ve to prior systemic therapy have been enrolled to sites in the USA. Pts receive afatinib QD (starting dose 30 mg/day) until disease progression/intolerable AEs. Dose reduction to 20 mg/day is permitted in the case of select Grade 2/3 AEs. The primary endpoint is the occurrence of AEs leading to dose reduction. Secondary endpoints include occurrence of Grade 3 diarrhoea and Grade 3 rash/acne, stomatitis and paronychia (grouped terms). Other endpoints are AEs by NCI CTCAE grade, objective response (OR), PFS and overall survival. Preliminary safety data are reported here. Results: As of 7 Feb 2018, 26 p

Who reads Is there a difference in PFS or OS of T790M-mutated NSCLC patients treated with osimertinib either after chemotherapy or immediately after previous target therapy??

Author

C.H. Lai; M.-C. Lin; Y.-H. Tsai; C.-C. Wang

Publisher

Oxford University Press; Elsevier BV (ISSN 0923-7534)

Published

2018

Language

EN

Field

Medicine (Health Sciences)